Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Clin North Am. 2006 May;33(2):161-6, v-vi.

Combined androgen blockade: an update.

Author information

1
Division of Urology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada. Laurence.klotz@sw.ca

Abstract

The use of combined androgen blockade therapy in prostate cancer management remains controversial. This article reviews the effect of the different non-steroid androgens in blocking androgen-independent activation of the androgen receptor in the androgen-depleted environment, and the potential benefit of bicalutamide in comparison to the first generation of anti-androgens (flutamide and nilutamide). An estimate of the benefit of combined therapy with bicalutamide suggests there is a high probability that bicalutamide 50 mg as combined therapy provides a survival advantage over castration alone. This treatment must be balanced against the potential for an increase in side-effects and a consequent adverse effect on the patient's quality of life.

PMID:
16631454
DOI:
10.1016/j.ucl.2005.12.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center